SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000882104-20-000114
Filing Date
2020-08-06
Accepted
2020-08-06 16:12:46
Documents
18
Effectiveness Date
2020-08-06

Document Format Files

Seq Description Document Type Size
1 DEFA14A pdli-20200806defa14adoc2.htm DEFA14A 29478
2 slide101.jpg GRAPHIC 135503
3 slide11.jpg GRAPHIC 52523
4 slide111.jpg GRAPHIC 136212
5 slide121.jpg GRAPHIC 154282
6 slide131.jpg GRAPHIC 112653
7 slide141.jpg GRAPHIC 176797
8 slide151.jpg GRAPHIC 133947
9 slide161.jpg GRAPHIC 111200
10 slide171.jpg GRAPHIC 30982
11 slide21.jpg GRAPHIC 234464
12 slide31.jpg GRAPHIC 147007
13 slide41.jpg GRAPHIC 124162
14 slide51.jpg GRAPHIC 137480
15 slide61.jpg GRAPHIC 120114
16 slide71.jpg GRAPHIC 126811
17 slide81.jpg GRAPHIC 134500
18 slide91.jpg GRAPHIC 167840
  Complete submission text file 0000882104-20-000114.txt   3112198
Mailing Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451
Business Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451 775-832-8500
PDL BIOPHARMA, INC. (Filer) CIK: 0000882104 (see all company filings)

IRS No.: 943023969 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-19756 | Film No.: 201081757
SIC: 2836 Biological Products, (No Diagnostic Substances)